CONTENTS

PREFACE AND ACKNOWLEDGMENTS xv

PART A  GENERAL CONCEPTS 1

1.  Introduction 3

  General Discussion, 3
  Key Definitions, 6
   The Interacting Parties, 6
   Extractables versus Leachables, 7
  Regulatory Perspectives for Performing Compatibility and/or
   Safety Assessments, 13
  The U.S. Food and Drug Administration Guidance for
   Industry: Container Closure Systems for Packaging Human
   Drugs and Biologics, 14
  European Medicines Agency (EMEA) Guideline on Plastic
   Immediate Packaging Materials, 15
  FDA Guidance for Industry, Inhalation Products, 18
  Medical Devices, 20
  An Overview of Strategies for Performing Safety
   Assessments, 21
  The Generalized Strategy for Safety Assessments, 22
  Moving Forward, 24
  References, 25
## 2. Nomenclature and General Concepts

General, 27  
Nomenclature, 27  
Primary Definitions, 28  
Constituents of a Material or Construct, 29  
Classification of Extracting Media, 31  
Classification of Extraction Strategies, 32  
Example Extraction Conditions Applied to a Model System, 39  
Correlation, 43  
Factors That Influence the Linking of Extractables and Leachables, 44  
A Hierarchy for Linkages between Extractables and Leachables, 44  
Decisions Concerning the Required Rigor for Linkages, 47  
Circumstances Requiring the Linking of Extractables and Leachables, 48  
Identification and Quantitation, 50  
Risks and Risk Management, 55  
Risk Categories Related to Biological Assessment of Medical Devices, 58  
Risk Categories Related to Assessment of Primary Packaging and/or Container–Closure Systems, 58  
The General Dimensions of Risk, 64  
Utilization of Risk Classification Profiles, 68  
Risk Classification in Indirect Contact Situations, 71  
The Construct Itself as a Contributor to Risk, 73  
References, 74

## 3. Extractables, Leachables, and the Product Life Cycle

General, 77  
Discussion of the Components of the Master Flow Diagram, 78  
Observations, 83  
Application of the Process Map, 87

### PART B  MATERIAL CHARACTERIZATION

### 4. Material Screening and Characterization

Overview, 91  
General Principles, 94
Compendial Compliance, 97
   United States Pharmacopeia, 98
   Japanese Pharmaceopeia, 101
   European Pharmacopeia, 102
Compositional Characterization, General Concepts, 103
Compositional Characterization by Collecting Available Material Information, 104
   General, 104
   Collecting Extractables Information from the Material Supplier, 106
Compositional Characterization by Material Testing,
   Extractables Survey, 112
   Extractables Survey: Extraction, 112
   Case Studies: The Influence of Extraction Medium on the Extractables Survey, 121
   Extractables Survey: Extract Analysis, 124
   Case Study: Extractables Survey for Plastic Tubing Materials, 131
   Case Study: Extractables Survey for an Elastomer Used in OINDP, 136
   Case Study: Extractables Survey for a Rubber Closure Used with Semisolid Drug Products, 137
   Case Study: Extractables Survey for Filter Cartridges Used in Downstream Processing of Pharmaceuticals, 138
Bibliography of Analytical Methods, 139
Reconciliation as a Survey Tool, 140
   Case Study: TOC Reconciliation; Characterization of a Polyolefin Material, 141
Use of Extractables Information in Safety Assessment:
   Extractables Profile, Total Pool, and Total Available Pool, 142
   Extractions to Establish the Total Pool and Total Available Pool, 143
   Case Study: Total Pool Determination by Successive Extraction, 145
Recap: Components of a Complete Extractables Assessment, 146
Caveats in Using Extractables Information for Safety Assessment, 149
Chemical Characterization: Device Perspective per ISO 10993-18, 152
References, 154
5. The Prototype Stage

General Comments, 159
The Simulation Study, 161
  Generating the Simulating Extract, 162
  Simulating the Contact Parameters, 164
  Simulating the Therapeutic Product, 166
  Simulating the Exposure Parameters, 169
  Analyzing the Simulating Extract, 171
  Case Study: Modeling of the Impact of Solubilizing Agents on Leachables Accumulation, 172
  Case Study: Accumulation of Organic Leachables from Plastic Biopharmaceutical Process Containers, 174
  Case Study: Accumulation of Label-Related Leachables in a Solid Dosage Form, 179
  Case Study: Accumulation of Caprolactam Oligomers Leached from Nylon-6 Material, 180
  Application of the Analytical Threshold, 181
The Preliminary Toxicological Assessment, 184
  Case Study: Assessment of Cyclohexanone Limits for Containers, 188
Exiting the Prototype Stage, 188
References, 189

6. The Early Development Stage

General Comments, 191
Target Leachables, 192
Method Development, Evaluation, and Validation, 194
  Method Development (Optimization), 195
  Prerequisites to Method Optimization, 195
  Overview of the Method Optimization Process, 197
  Conduct of a Method Optimization Study, 200
  Primary Performance Assessment, 201
  Troubleshooting Guide, 202
  Secondary Performance Assessment, 204
  System Suitability, 205
  Robustness, 205
  Exiting Method Development–Optimization, 206
The Method Evaluation Process, 206
  General, 206
  Aspects of the Evaluation and Validation Processes, 207
Overview of the Method Evaluation Process, 207
Template for the Conduct of a Method Evaluation Study, 209
Validation, 214
Case Study: Validation of an LC/MS Method for the
Quantitation of Leachables from a Packaging System, 215
General, 215
Experimental, 216
Validation Study, 218
Case Study: Validation of an HPLC Method For Quantitating
Stopper Leachables in a Complex Surfactant Vehicle, 225
General, 225
Validation, 225
Exiting the Early Development Stage, 228
References, 228

PART D CONSTRUCT VALIDATION

7. Late Stage Product Development

General: The Migration Study, 231
Design of the Migration Study, 233
  EMEA Guideline on Plastic Immediate Packaging
  Materials, 233
  FDA Guidance, 233
  Optimal Design of a Migration Study, 234
Interpretation of the Migration Study: Toxicological
  Assessment, 238
Disaster Management, 238
  Class A Disaster: Unusual or Unexpected Change in the
  Concentration of a Target Leachable, 239
  Class B Disaster: A Previously Unobserved Response Is
  Obtained During Testing, 241
  Documenting a Disaster Investigation, 242
Specificity Check in Drug Product Analysis Methods, 242
Product Stability Issues Associated with Leachables, 244
References, 245

8. Submission

General Discussion, 249
CONTENTS

Contents of the CTD Sections Relevant to Container Closure Systems and Their Safety Assessment, 252
Section 3.2.P7, Description, 252
Section 3.2.P2.4, Suitability, 254
Closing Observations, 262
References, 263

9. Launch 265

PART E PRODUCT MAINTENANCE 271

10. Product Maintenance 273

General Discussion, 273
Ongoing Quality Control, 275
   General, 275
   Incoming Raw Materials, 275
   Manufactured In-Process Goods, 278
   Finished Goods (Final Product), 279
   Process of Developing–Implementing QC Extractables Specifications, 281
Change Control, 282
   General, 282
   Change Control Impact Assessment, 285
   Evaluation Recommendation, 295
   Factors to Consider When Contemplating Changes to Registered Products, 296
Case Study: Differential Approach, 297
   Overview, 297
   General Test Strategy, 297
   Experimental, 298
   Results and Discussion, 299
Principles for Judging Toxicological Equivalency, 304
Disaster Management During Product Maintenance, 305
   Atypical Manufacturing During Product Maintenance, 305
   Product Use Field Issues Encountered During Product Maintenance, 309
Changes in Product Registration Requirements During Product Maintenance, 312
Exiting the Product Maintenance Stage, 313
References, 313
11. Retirement 315

12. Focus on Emerging Concepts 319

Overview, 319
Plastic Materials used in Manufacturing Applications, 320
   General, 320
   Regulatory Requirements, 321
   Industry Recommendations, 322
Case Study: Leachables Evaluation for Bulk Drug Substance, 326
Process for Performing Extractables and Leachables Assessments for Disposable Materials Used in Bioprocessing, 327
A Matter of Semantics, 328
Best Demonstrated Practices in Extractables Assessments, 331
The Broader Context of Suitability for Use, 337
An Important Practical Consideration, 340
Future Considerations, 342
References, 344

Appendix: Materials Used in Pharmaceutical Constructs and Their Associated Extractables 347
   References, 370

INDEX 371